[go: up one dir, main page]

CL2014003283A1 - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation

Info

Publication number
CL2014003283A1
CL2014003283A1 CL2014003283A CL2014003283A CL2014003283A1 CL 2014003283 A1 CL2014003283 A1 CL 2014003283A1 CL 2014003283 A CL2014003283 A CL 2014003283A CL 2014003283 A CL2014003283 A CL 2014003283A CL 2014003283 A1 CL2014003283 A1 CL 2014003283A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
CL2014003283A
Other languages
Spanish (es)
Inventor
Andrew Jeffrey Yates
James Gregory Clipstone
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003283(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of CL2014003283A1 publication Critical patent/CL2014003283A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CL2014003283A 2012-06-21 2014-11-28 Pharmaceutical formulation CL2014003283A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261662621P 2012-06-21 2012-06-21

Publications (1)

Publication Number Publication Date
CL2014003283A1 true CL2014003283A1 (en) 2016-04-01

Family

ID=48745904

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003283A CL2014003283A1 (en) 2012-06-21 2014-11-28 Pharmaceutical formulation

Country Status (25)

Country Link
US (1) US20150150979A1 (en)
EP (1) EP2864356A1 (en)
JP (1) JP6157611B2 (en)
KR (1) KR20150032941A (en)
CN (1) CN104520326A (en)
AR (1) AR091530A1 (en)
AU (1) AU2013279347A1 (en)
BR (1) BR112014031841A2 (en)
CA (1) CA2876012A1 (en)
CL (1) CL2014003283A1 (en)
CO (1) CO7170174A2 (en)
EA (1) EA201590061A1 (en)
EC (1) ECSP15002095A (en)
HK (1) HK1205146A1 (en)
IL (1) IL235921A0 (en)
MA (1) MA37777B1 (en)
MX (1) MX2014014717A (en)
NZ (1) NZ702342A (en)
PE (1) PE20150190A1 (en)
PH (1) PH12014502596A1 (en)
SG (1) SG11201407779YA (en)
TN (1) TN2014000498A1 (en)
TW (1) TW201406398A (en)
WO (1) WO2013190047A1 (en)
ZA (1) ZA201409020B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
CA2962768C (en) 2014-10-01 2023-10-10 Alyssa M. Larson Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US11738036B2 (en) 2016-05-28 2023-08-29 Rajiv Gandhi Centre For Biotechnology, An Autonomous Institute Under The Department Of Biotechnology, Government Of India Uttroside B and derivatives thereof as therapeutics for hepatocellular carcinoma
BR112019006853B1 (en) * 2016-10-31 2021-08-24 Fresenius Kabi Deutschland Gmbh LIQUID PHARMACEUTICAL COMPOSITION, ITS MANUFACTURING METHOD, ITS USE, KIT AND DRUG RELEASE DEVICE INCLUDING IT AND MANUFACTURING METHOD OF SUCH DEVICE
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
CA3049857A1 (en) * 2017-01-11 2018-07-19 Celltrion Inc. Stable liquid formulation
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CA3198795A1 (en) 2020-11-18 2022-05-27 Jeffrey Becker Complexing agent salt formulations of pharmaceutical compounds
WO2022109052A1 (en) * 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332402T5 (en) * 2000-10-12 2018-05-14 Genentech, Inc. Concentrated protein formulations of reduced viscosity
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
HRP20050934B1 (en) * 2003-04-04 2014-09-26 Genentech, Inc. FORMULATIONS WITH HIGH CONCENTRATION OF ANTIBODIES AND PROTEINS
WO2006096490A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
TW200837080A (en) * 2007-01-09 2008-09-16 Wyeth Corp Anti-IL-13 antibody formulations and uses thereof
LT2170390T (en) * 2007-06-14 2019-01-10 Biogen Ma Inc. Natalizumab antibody formulations
RU2012151500A (en) * 2010-05-03 2014-06-10 Дженентек, Инк. COMPOSITIONS AND METHODS SUITABLE FOR REDUCING VISCOSITY OF PROTEIN-CONTAINING COMPOSITIONS
SMT202000095T1 (en) * 2010-05-14 2020-03-13 Amgen Inc High concentration anti-sclerostin antibody formulations
JP2013531679A (en) * 2010-07-02 2013-08-08 メディミューン,エルエルシー Antibody preparation
US20140044727A1 (en) * 2011-04-07 2014-02-13 Glaxosmithkline Llc Formulations with reduced viscosity
CA2831572C (en) * 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration

Also Published As

Publication number Publication date
AU2013279347A1 (en) 2014-12-18
MX2014014717A (en) 2015-03-06
ZA201409020B (en) 2016-09-28
HK1205146A1 (en) 2015-12-11
PE20150190A1 (en) 2015-02-13
NZ702342A (en) 2016-07-29
ECSP15002095A (en) 2015-11-30
TN2014000498A1 (en) 2016-03-30
IL235921A0 (en) 2015-01-29
CA2876012A1 (en) 2013-12-27
JP2015520206A (en) 2015-07-16
KR20150032941A (en) 2015-03-31
AR091530A1 (en) 2015-02-11
EA201590061A1 (en) 2015-05-29
SG11201407779YA (en) 2015-02-27
EP2864356A1 (en) 2015-04-29
MA20150436A1 (en) 2015-11-30
CN104520326A (en) 2015-04-15
US20150150979A1 (en) 2015-06-04
JP6157611B2 (en) 2017-07-05
WO2013190047A1 (en) 2013-12-27
CO7170174A2 (en) 2015-01-28
MA37777B1 (en) 2017-07-31
BR112014031841A2 (en) 2017-06-27
TW201406398A (en) 2014-02-16
PH12014502596A1 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
DK3181128T3 (en) NILOTINIB PHARMACEUTICAL COMPOSITION
BR112014028602A2 (en) liquid formulation.
DK3030262T3 (en) COMBINED PHARMACEUTICAL COMPOSITION
SI3725778T1 (en) Enzalutamide formulations
BR112015002738A2 (en) compound and pharmaceutical composition
DK2858671T3 (en) antibody Formulation
DK2890397T3 (en) ANTIPROLACTINRECEPTOR antibody formulation
PT2854768T (en) PEMETREXED PHARMACEUTICAL COMPOSITIONS
BR112015003259A2 (en) compound, pharmaceutical composition, and vaccine composition.
DK2900645T3 (en) HERBICID ACTIVE 3-PHENYLISOXAZOLINE DERIVATIVES
CL2014003283A1 (en) Pharmaceutical formulation
DK2897594T3 (en) PHARMACEUTICAL COMPOSITION
CO6940426A2 (en) Pharmaceutical formulations
DK2868318T4 (en) INJECTIBLE FORMULATION
EP2838488A4 (en) DRUG DISTRIBUTORS
EP2883547A4 (en) DRUG
FR2986872B1 (en) .
DK2854765T3 (en) PHARMACEUTICAL PEMETREXED SOLUTION
BR112014032501A2 (en) compound and pharmaceutical composition.
BR112014028443A2 (en) sterile composition.
CO7091176A2 (en) Pharmaceutical diagnosis
DK3473255T3 (en) PHARMACEUTICAL FORMULATION INCLUDING CICLESONIDE
DK3003401T3 (en) PHARMACEUTICAL PREPARATION
DK3427723T3 (en) RNA FORMULATION FOR IMMUNTERAPHY
BR112014027645A2 (en) 5-halopyrazole biphenylcarboxamides.